Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
Revenue of Intensity Therapeutics, Inc. (INTS)
Revenue in 2023 (TTM): $
According to Intensity Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Intensity Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-147,000 | $-8,172,000 | $-10,538,000 | $-10,538,000 |
| 2022 | $ | $-179,037 | $-7,501,185 | $-7,582,966 | $-7,451,058 |
| 2021 | $ | $ | $-8,013,722 | $-7,895,600 | $-7,892,991 |
| 2020 | $ | $ | $-6,223,246 | $-6,030,480 | $-5,956,471 |
| 2019 | $ | $ | $-5,675,532 | $-5,379,836 | $-5,229,129 |